Zila's OraTest Rinse Needs Additional Study, FDA Advisory Committee Says
This article was originally published in The Gray Sheet
Executive Summary
Zila should conduct another trial of its OraTest oral cancer diagnostic, FDA's Oncology Drugs Advisory Committee determined Jan. 13.
You may also be interested in...
Zila’s OraTest Oral Cancer Screen Lags At CDER; ZTC Clears Premarket Hurdle
Zila Medical's strategy of seeking an adjunctive claim for its ZTC tolonium chloride compound enabled a relatively quick device review, CEO Douglas Burkett said in a Feb. 7 conference call
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.